2型糖尿病肾脏疾病C_(D-d)/C_(IgG)的变化及意义被引量：1

下载PDF

导出

摘要目的:探讨2型糖尿病(T2DM)肾脏疾病(T2DKD)患者D-二聚体清除率与IgG清除率比(CD-d/CIgG)的变化及临床价值。方法:根据尿微量白蛋白/尿肌酐比(urinary albumin creatinine ratio,UACR)将199例T2DM患者分为单纯糖尿病组(SDM组,60例)﹑早期糖尿病肾脏疾病组(EDKD组,60例)和临床糖尿病肾脏疾病组(CDKD组,79例),另选健康体检者作为对照组(NC组,50例),分别测定各组血浆D-d(sD-d)、IgG(sIgG)及尿D-d(uD-d)、IgG(uIgG)浓度计算出CD-d/CIgG,并进行组间比较。结果:SDM组、EDKD组、CDKD组CD-d/CIgG、sD-d、uD-d较NC组升高(P<0.05),随病情加重,升高更为明显。CD-d/CIgG与hs-CRP显著相关(r=0.63,P<0.05)。T2DKD患者CD-d/CIgG水平随着尿白蛋白的增加而升高。结论:T2DM患者CD-d/CIgG水平明显升高,可作为T2DKD早期敏感的诊断指标。

作者张国明胡礼仪戎国栋韩洪波周业庭马小波

机构地区江苏省沭阳县人民医院南京医科大学第一附属医院

出处《实用医学杂志》 CAS 北大核心 2012年第1期96-98,共3页 The Journal of Practical Medicine

关键词糖尿病 2型肾脏疾病 D-二聚体 IGG 清除率尿白蛋白

分类号 R692 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献8

1Lehmann R, Schleiher E D. Molecular mechanism of diabetic nephropathy [ J]. Clin Chim Acta, 2000,297 ( 1 ) : 135.
2Friedman A N, Hunsicker L G, Selhub J, et al. Clinical andnuitritional correlates of C-reactive protein in type 2 diabetic nephropathy [J]. Atherosclerosls, 2004,172( 1 ) : 121-125.
3Yamada T, Sato A, Nishimori T. Importance of hyperc- oagulability over hyperglycemia for vascular complication in type 2 diabetes[J]. Diabetes Res Clin Pract,2000,49(1):13- 31.
4Nation Kidney Foundation. KDOQI^TM clinical practice guideline and clinicalpractice recommendation for diabetes and chronic kidney disease[J]. Am J Kidney Dis,2007,49 (Suppl 2):S1- S180.
5Rao P V, Lu X, Standley M, et al. Proteomic identification of urinary biomarkers of diabetic nephropathy [J]. Diabetes Care, 2007,30 (3) : 629-637.
6卢文,郝丽,司力.肾病综合征患者凝血分子标志物测定的临床价值[J].实用医学杂志,2005,21(7):682-684. 被引量：8
7李春仙,史训忠.2型糖尿病肾病患者血D-二聚体、纤维蛋白原、C反应蛋白水平的临床意义[J].检验医学,2010,25(2):107-109. 被引量：37
8Vaxlrl N D. Plasma levels and urinary excretion of fibrinolytic: and protease inhibitory proteins in nephrotic syndrome [J]. Lab Clin Med, 1994,124( 1 ) : 118-123.

二级参考文献12

1李秀钧,邬云红.糖尿病是一种炎症性疾病?[J].中华内分泌代谢杂志,2003,19(4):251-253. 被引量：254
2Yamada T, Sato A, Nishimori T, et al. Importance of hypercoagulability over hyperglycemia for vascular complication in type 2 diabetes[J].Diabetes Res Clin Pract, 2000, 49 (1) : 23-31.
3Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients [J]. Arteriosclerosis Thromb and Vascular Biol, 2000, 20(6) : 1595-1599.
4Nickolas TL, Radhakrishnan J, Appel GB. Hyperlipidemia and thrombotic complications in patients with membranousnephropathy. Semi Nephrol,2003,23(4): 406-411.
5Couser WG. Pathogenesis of glomerular damage in glomerulonephritis. Nephrol Dial Transplant, 1998,13(Suppl 1):10-15.
6Frijns CJ, Derksen RH, De-Groot PG, et al. lupus anticoagulant and history of thrombosis are not associated withpersistent endothelial cell activation in systemic lupus erythematosus. Clin Exp Immunol, 2001,125(1): 149-154.
7Atsumi T, Khamashta MA, Andujar C, et al. Elevated plasma lipoprotein(a) level and its association with impairedfibrinolysis in patients with antiphospholipid syndrome. J Rheumatology, 1998,25(1): 69-73.
8Kim V, Spandorfer J. Epidemiology of venous thromboembolic disease. Emerg Med Clin North Am, 2001,19(4): 839-859.
9Tkaczyk M,Owczarek D,Puczko-Nogal B,et al. Activation of coagulation cascade in children during an idiopathic nephrotic syndrome relapse,Pol Merkuriusz Lek,2000,8(46): 226-227.
10李家增.弥散性血管内凝血——弥散性血管内凝血的病因和发病机制[J].中国实用内科杂志,2000,20(6):323-324. 被引量：8